Osteoinductive Effects of Cyplexinol in the Management of Osteoporosis: A Case Series.

ABSTRACT

Aims • A case study was conducted on a subject with a history of documented bone loss and the observed outcome of bone mineral density (BMD) changes when utilizing supplementation with Cyplexinol, a natural bone morphogenetic protein complex. Method and Results • A case of osteoporosis was reviewed with pertinent medical history and dual energy X-ray absorptiometry history described both pre- and postsupplementation. Results demonstrated a significant change in bone density parameter for the individual when the bone support supplement, Cyplexinol, was used. Given this promising initial result, 3 additional cases were reviewed for potential replication and generalizability. Results showed a range of positive bone density changes of 18.5% to 63.63% during a supplementation period of 2 to 5 y. Conclusions • Cyplexinol may effectively manage BMD loss experienced during osteoporosis, though more studies are warranted with larger samples to replicate these findings. Given that administration of Cyplexinol was found to improve density scores in both mild and severe cases, despite the extent of the patient's history of documented bone loss, Cyplexinol has a more diverse range of applicability than prescription medications, suggesting the first, natural alternative to bisphosphonates, hormone replacement therapies and antireceptor activator of nuclear factor kappa-B ligand (anti-RANKL) agents. Furthermore, due to Cyplexinol's safety profile of no known side effects, it may be the ideal long-term strategy for individuals with bone loss and a possible preventative agent for individuals with known risk factors (eg, cigarette use, alcohol and carbonated drink usage, calcium deficiency, and family history) for osteoporosis. Although a larger pool of subjects is necessary to further support Cyplexinol's role in managing osteoporosis, these data are consistent with other studies examining the benefits of Cyplexinol's protein complex on BMD loss as a potential new, orally bioavailable therapeutic for the effective treatment of osteoporosis.